Merck to Host Second Quarter 2022 Sales and Earnings Conference Call on July 28

0

RAHWAY, NJ–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, will hold its second quarter 2022 sales and earnings conference call with institutional investors and analysts at 8 a.m. ET on Thursday, 28 July. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook.

Investors, journalists and the general public can access a live audio webcast of the call via this web link. A replay of the webcast, along with the sales and earnings press release, additional financial information and slides highlighting the results, will be available at www.merck.com.

Participants can join the call by dialing 877-692-8955 (US toll-free) or 234-720-6979. If you are calling from other countries, visit this web link. All attendees can use the access code 1857604. Journalists who wish to ask questions should contact a member of Merck’s Media Relations team.

About Merck
At Merck, known as MSD outside the United States and Canada, we are united around our purpose: We use the power of cutting-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the world’s leading research-intensive biopharmaceutical company – and today we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of disease in humans and animals. We foster a diverse and inclusive global workforce and act responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and join us on Twitter, Facebook, instagram, Youtube and LinkedIn.

Merck & Co., Inc., Rahway, NJ, USA Forward-Looking Statement
This press release from Merck & Co., Inc., Rahway, NJ, USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and around the world; global trends toward health care cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and/or regulatory actions.

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Other factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and other company filings. with the Securities and Exchange Commission. (SEC) available on the SEC’s website (www.sec.gov).

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220629005168/en/

contacts

Media:
Johanna Hermann
(617) 216-6029

Melissa Moody
(215) 407-3536

Investors:
Pierre Dannenbaum
(908) 740-1037

Steven Graziano
(908) 740-6582

Source: Merck & Co., Inc.

Powered by Business Wire

Read this press release online at:

http://www.businesswire.com/news/home/20220629005168/en



Source link

Share.

Comments are closed.